| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | -0.2 | 0.2 |
| Profit before tax | -96.4 | -163.0 |
| Net income | -96.3 | -163.1 |
| EPS (diluted, $ a share) | $-0.57 | $-1.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: VIR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vir Biotechnology, Inc.: key numbers
- Share price
- $9.58Close, Nov 16
- Market cap
- $1.64B
- Shares outstanding
- 171.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vir Biotechnology, Inc.
All →Vir Biotechnology Capital Raise of $150M
Vir Biotechnology entered into an underwriting agreement to sell 15,000,000 shares of common stock at a public offering price of $10.00 per share. The company expects to receive approximately $140.4 million in net proceeds, or $161.5 million if the underwriters exercise their 30-day option to purchase an additional 2,250,000 shares.
- Value
- $150M
- Counterparty
- Leerink Partners LLC
Vir Biotechnology Clinical Trial Data
Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.
Vir Biotechnology Financial Results
Vir Biotechnology reported third-quarter 2026 financial results, ending the period with $901 million in cash and investments. The company highlighted upcoming Phase 3 data for its hepatitis delta program and the receipt of FDA Fast Track designation for its oncology candidate VIR-5500.
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
Vir Biotechnology EVP, General Counsel, Corp Sec Verneuil Vanina de Sells $41.9K of Stock
Verneuil Vanina de, EVP, General Counsel, Corp Sec, sold 3,750 shares of Vir Biotechnology, Inc. at $11.10 to $11.33 a share (average $11.18) in 2 transactions, worth $41.9K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 110,193 (-2.1%).
- Value
- $41.9K
- Shares
- 3,750
- Average price
- $11.18
- Role
- EVP, General Counsel, Corp Sec
- Holding change
- -2.1%
- Trade date
- Nov 2, 2026 to Nov 3, 2026
Vir Biotechnology Executive Compensation
Vir Biotechnology appointed Suzanne Topalian, M.D., to its Board of Directors and the Science and Technology Committee, effective October 27, 2026. As a non-employee director, she will receive standard cash and equity compensation, including stock options and restricted stock units under the company's 2019 Equity Incentive Plan. The board size was increased from eight to nine members to accommodate the appointment.
- Counterparty
- Suzanne Topalian, M.D.
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
- Value
- $1.88B
- Counterparty
- Gilead Sciences, Inc.